SCHEMBL25476856

SCHEMBL25476856

CC(=O)C1CCCN1C(=O)NCc1nc([C@@H](N)CCC(=O)O)no1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 2/20 0.37
▸ REN P00797 1/20 0.37
▸ F2 P00734 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ DPP4 P27487 2/20 0.33
▸ FKBP1A P62942 2/20 0.33
▸ FAP Q12884 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.33
▸ DPP9 Q86TI2 1/20 0.33
▸ DPP7 Q9UHL4 1/20 0.33
▸ POLB P06746 2/20 0.32
▸ USP2 O75604 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25476847 0.93 F2 (0.36) F2CYP3A4CYP2C9PKMCYP2C19
SCHEMBL21168279 0.92 ACE (0.43) ACERENCYP3A4CYP2C9PKM
SCHEMBL21168328 0.92 ACE (0.43) ACERENCYP3A4CYP2C9PKM
SCHEMBL25476858 0.88 DPP4 (0.34) ACEF2CYP3A4CYP2C9PKM
SCHEMBL21168327 0.87 ACE (0.39) ACERENCYP3A4CYP2C9PKM
SCHEMBL21168276 0.86 ACE (0.35) ACERENF2CYP3A4CYP2C9
SCHEMBL21168332 0.86 ACE (0.35) ACERENF2CYP3A4CYP2C9
SCHEMBL25476852 0.84 CYP3A4 (0.46) ACEF2CYP3A4CYP2C9PKM
SCHEMBL21168380 0.83 FKBP1A (0.35) ACERENF2CYP3A4CYP2C9
SCHEMBL25476876 0.83 ACE (0.37) ACERENDPP4FAPDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144653-A1 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways AURIGENE ONCOLOGY LIMITED (IN) 2023-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144653-A1 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways CD47, HIF1AN, PIK3R5 ACE 4811/4885REN 4143/4885F2 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback